Efeito analgésico da melatonina em um modelo animal da síndrome de dor complexa regional tipo I

Detalhes bibliográficos
Autor(a) principal: Mack, Josiel Mileno
Data de Publicação: 2013
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Manancial - Repositório Digital da UFSM
dARK ID: ark:/26339/0013000005m8c
Texto Completo: http://repositorio.ufsm.br/handle/1/28415
Resumo: Complex regional pain syndrome-type I (CRPS-I) affects upper or lower limbs distal parts, leading symptoms like chronic pain, edema, trophic changes and motor function abnormalities. This syndrome commonly follows factures and sprains. The pathophysiology of CRPS-I is not completely understood and its suggested that microvessels changes related to the syndrome maintenance lead to a reduction in oxygen supply. In this study the objective was to evaluation the time course of the antinociceptive activity of melatonin, an endogenous indolamine released mainly by pineal gland, in the mechanical and cold hypersensitivity and in the edema presented in the chronic post-ischemic pain (CPIP) in mice; an animal model of human CRPS-I, and participation of MT1/MT2 receptors and oxidative stress in this model. The antinociceptive activity of melatonin in the nociception evoked by TRPs (transient receptors potential) and ASICs (acid-sensing ion channels). CPIP was induced in Swiss male mice by placing a tourniquet proximal to the ankle joint for 3 hours, followed by removal to allow tissue reperfusion. The mechanical (0.4 g von Frey filaments) and cold (cold plate 4 ºC) hypersensitivity was mensured on second and seventh days after reperfusion. Catalase (CAT), glutathione reductase (GR) and glutathione peroxidase (GPx) enzyme activity and malondialdehyde (MDA) levels were measured 2 h, 2 and 7 days after reperfusion, tissues were collected 30 min after melatonin treatment (100 mg/kg, i.p.). Melatonin activity (10 – 100 mg/kg, i.p., or 10 – 100 ng/paw, i.pl.) was also evaluated by measuring of nociception evoked by TRPV1 agonists (capsaicin, 30,5 ng/paw, i.pl.), TRPA1 (cinnamaldehyde, 1,32 μg/paw), TRPM8 (menthol, 1.2 μg/paw) and ASICs (acetic acid 2%, pH 1.98). The treatment with melatonin (10-100 mg/kg, i.p.) dose-dependently reduced the mechanical hypersensitivity 2 and 7 days after reperfusion and with 100 mg/kg the effect remained by for up 2 h after administration. Furthermore, the treatment with melatonin (100 mg/kg, i.p.) also reduced the cold hypersensitivity 2 and 7 days after reperfusion. However, the melatonin effect (100 mg/kg) was not affected by pretreatment with luzindole (10 mg/kg, i.p., non-selective MT1/MT2 antagonist). The melatonin (100 mg/kg, i.p.) also reduced the edema evoked by CPIP in the second day after reperfusion. GR enzyme activity was reduced 2 h after reperfusion and melatonin treatment didn´t change this parameter. GR and GPx, and, Cat and GPx enzymes activities were elevated on days 2 and 7, respectively, and melatonin reversed this increase. The systemic administration (i.p.) of melatonin inhibited the nociception evoked by capsaicin, cinnamaldehyde, menthol and acid saline, inhibitions of 63 + 16%, 41 + 13%, 62 + 10% e 47 + 12%, respectively. Moreover, the peripheral administration of melatonin only inhibited the nociception evoked by capsaicin (49 + 6%) and cinnamaldehyde (60 + 6%). In conclusion, this study extends the literature and shows that melatonin is able to reduce the mechanical and thermal hypersensitivity and the edema in the CPIP model, probably by a modulation of redox status of the cell through its antioxidant properties and inhibition of peripheral nociceptors.
id UFSM_529552ca79ca50c1682a55a995b79798
oai_identifier_str oai:repositorio.ufsm.br:1/28415
network_acronym_str UFSM
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling Efeito analgésico da melatonina em um modelo animal da síndrome de dor complexa regional tipo IAntioxidant-analgesic effect of melatonin in a animal model of complex regional pain syndrome type ISíndrome de dor complexa regional tipo IDor crônica pós-isquemiaMelatoninaEstresse oxidativoEnzimas antioxidantesComplex regional pain syndrome-type IChronic post-ischemic painMelatoninOxidative stressAntioxidant enzymesCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIAComplex regional pain syndrome-type I (CRPS-I) affects upper or lower limbs distal parts, leading symptoms like chronic pain, edema, trophic changes and motor function abnormalities. This syndrome commonly follows factures and sprains. The pathophysiology of CRPS-I is not completely understood and its suggested that microvessels changes related to the syndrome maintenance lead to a reduction in oxygen supply. In this study the objective was to evaluation the time course of the antinociceptive activity of melatonin, an endogenous indolamine released mainly by pineal gland, in the mechanical and cold hypersensitivity and in the edema presented in the chronic post-ischemic pain (CPIP) in mice; an animal model of human CRPS-I, and participation of MT1/MT2 receptors and oxidative stress in this model. The antinociceptive activity of melatonin in the nociception evoked by TRPs (transient receptors potential) and ASICs (acid-sensing ion channels). CPIP was induced in Swiss male mice by placing a tourniquet proximal to the ankle joint for 3 hours, followed by removal to allow tissue reperfusion. The mechanical (0.4 g von Frey filaments) and cold (cold plate 4 ºC) hypersensitivity was mensured on second and seventh days after reperfusion. Catalase (CAT), glutathione reductase (GR) and glutathione peroxidase (GPx) enzyme activity and malondialdehyde (MDA) levels were measured 2 h, 2 and 7 days after reperfusion, tissues were collected 30 min after melatonin treatment (100 mg/kg, i.p.). Melatonin activity (10 – 100 mg/kg, i.p., or 10 – 100 ng/paw, i.pl.) was also evaluated by measuring of nociception evoked by TRPV1 agonists (capsaicin, 30,5 ng/paw, i.pl.), TRPA1 (cinnamaldehyde, 1,32 μg/paw), TRPM8 (menthol, 1.2 μg/paw) and ASICs (acetic acid 2%, pH 1.98). The treatment with melatonin (10-100 mg/kg, i.p.) dose-dependently reduced the mechanical hypersensitivity 2 and 7 days after reperfusion and with 100 mg/kg the effect remained by for up 2 h after administration. Furthermore, the treatment with melatonin (100 mg/kg, i.p.) also reduced the cold hypersensitivity 2 and 7 days after reperfusion. However, the melatonin effect (100 mg/kg) was not affected by pretreatment with luzindole (10 mg/kg, i.p., non-selective MT1/MT2 antagonist). The melatonin (100 mg/kg, i.p.) also reduced the edema evoked by CPIP in the second day after reperfusion. GR enzyme activity was reduced 2 h after reperfusion and melatonin treatment didn´t change this parameter. GR and GPx, and, Cat and GPx enzymes activities were elevated on days 2 and 7, respectively, and melatonin reversed this increase. The systemic administration (i.p.) of melatonin inhibited the nociception evoked by capsaicin, cinnamaldehyde, menthol and acid saline, inhibitions of 63 + 16%, 41 + 13%, 62 + 10% e 47 + 12%, respectively. Moreover, the peripheral administration of melatonin only inhibited the nociception evoked by capsaicin (49 + 6%) and cinnamaldehyde (60 + 6%). In conclusion, this study extends the literature and shows that melatonin is able to reduce the mechanical and thermal hypersensitivity and the edema in the CPIP model, probably by a modulation of redox status of the cell through its antioxidant properties and inhibition of peripheral nociceptors.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESA síndrome de dor complexa regional tipo I (SDCR-I) é uma patologia que atinge membros superiores ou inferiores de forma distal, levando a sintomas como dor crônica, edema, alterações tróficas e comprometimento motor. Esta síndrome geralmente tem início após lesões como fraturas e torções. A patofisiologia da SDCR-I ainda não é completamente entendida, porém, sugere-se que uma redução no aporte de oxigênio devido a alterações microvasculares esteja relacionada a manutenção da síndrome. O presente trabalho teve como objetivo avaliar a atividade antinociceptiva da melatonina, uma indolamina endógena liberada principalmente pela glândula pineal, na hipersensibilidade mecânica e térmica (ao frio) presente no modelo de dor crônica pós-isquemia (DCPI) em camundongos, o qual mimetiza os sinais e sintomas da SDCR-I em humanos, bem como a participação dos receptores MT1/MT2 e do estresse oxidativo neste efeito. A indução da DCPI em camundongos Suíços machos foi feita através do posicionamento de um torniquete próximo ao tornozelo dos animais, o qual foi mantido por 3 horas, seguido da remoção para permitir a reperfusão dos tecidos. A hipersensibilidade mecânica (através do filamento de Von Frey, 0,4 g) e térmica (placa fria, 4º C) e o edema da pata foram avaliados no segundo e no sétimo dia após a reperfusão. Além disto, foi analisada a atividade das enzimas catalase (CAT), glutationa redutase (GR) e glutationa peroxidase (GPx) e a imunorreatividade ao aduto malondialdeído-preteína (MDA) 2 h, 2 e 7 dias após a reperfusão, sendo que os tecidos foram coletados 30 min após o tratamento com melatonina (100 mg/kg, i.p.). O efeito da melatonina (10 – 100 mg/kg, i.p., ou 10 – 100 ng/pata, i.pl.) também foi avaliada frente à nocicepção espontânea evocada por agonistas de TRPV1 (capsaicina 30,5 ng/pata), TRPA1 (cinamaldeído 1,32 μg/pata), TRPM8 (mentol 187,5 μg/pata) e ASICs (salina acidificada, pH 1,98). A melatonina (10-100 mg/kg, i.p.) reduziu de forma dependente da dose a hipersensibilidade mecânica no segundo e no sétimo dia após a reperfusão, sendo que na dose de 100 mg/kg seu efeito persistiu por até 2 horas após a administração. Além disto, a melatonina (100 mg/kg, i.p.) também reduziu a hipersensibilidade térmica (ao frio) no segundo e no sétimo dia após a reperfusão. Contudo, o efeito da melatonina (100 mg/kg, i.p.) na hipersensibilidade mecânica e térmica (placa fria) não foi alterada pela administração prévia de luzindol (10 mg/kg, i.p., antagonista não-seletivo de receptores MT1/MT2). O tratamento com melatonina (100 mg/kg, i.p.) também reverteu o edema gerado pela indução de DCPI. A atividade da enzima GR se apresentou reduzida 2 h após a reperfusão, e o tratamento com melatonina não alterou esse parâmetro. A atividade das enzimas GR e GPx, e CAT e GPx, se apresentou aumentada no segundo e no sétimo dia, respectivamente, sendo que o tratamento com melatonina reverteu este aumento. A administração sistêmica de melatonina (via i.p.) foi capaz de inibir a nocicepção evocada pela capsaicina, cinamaldeído, mentol e salina acidificada, com inibição de 63 + 16%, 41 + 13%, 62 + 10% e 47 + 12%, respectivamente. Além disto, a administração periférica da melatonina (via i.pl.) inibiu somente a resposta evocada pela capsaicina (49 + 6%) e cinamaldeído (60 + 6%). Em conclusão este estudo estendeu os dados da literatura demonstrando que a melatonina foi capaz de reduzir a hipersensibilidade mecânica e térmica (ao frio) e o edema provocados pela indução do modelo de DCPI em camundongos. O seu mecanismo de ação não está completamente elucidado, contudo, o efeito da melatonina provavelmente depende da sua ação antioxidante através da modulação do estado redox da célula e por consequência da atividade das enzimas antioxidantes, podendo também estar atuando através da inibição da transmissão nociceptiva por inibir a ativação de nociceptores periféricos, em especial dos TRPV1 e TRPA1.Universidade Federal de Santa MariaBrasilFarmacologiaUFSMPrograma de Pós-Graduação em FarmacologiaCentro de Ciências da SaúdeSantos, Adair Roberto Soares doshttp://lattes.cnpq.br/9263042062534666Mello, Carlos Fernando deNascimento, Francisney Pinto doFurian, Ana FláviaMack, Josiel Mileno2023-03-27T14:36:23Z2023-03-27T14:36:23Z2013-02-18info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://repositorio.ufsm.br/handle/1/28415ark:/26339/0013000005m8cporAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2023-03-27T14:36:23Zoai:repositorio.ufsm.br:1/28415Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2024-07-29T10:25:03.155721Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.none.fl_str_mv Efeito analgésico da melatonina em um modelo animal da síndrome de dor complexa regional tipo I
Antioxidant-analgesic effect of melatonin in a animal model of complex regional pain syndrome type I
title Efeito analgésico da melatonina em um modelo animal da síndrome de dor complexa regional tipo I
spellingShingle Efeito analgésico da melatonina em um modelo animal da síndrome de dor complexa regional tipo I
Mack, Josiel Mileno
Síndrome de dor complexa regional tipo I
Dor crônica pós-isquemia
Melatonina
Estresse oxidativo
Enzimas antioxidantes
Complex regional pain syndrome-type I
Chronic post-ischemic pain
Melatonin
Oxidative stress
Antioxidant enzymes
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
title_short Efeito analgésico da melatonina em um modelo animal da síndrome de dor complexa regional tipo I
title_full Efeito analgésico da melatonina em um modelo animal da síndrome de dor complexa regional tipo I
title_fullStr Efeito analgésico da melatonina em um modelo animal da síndrome de dor complexa regional tipo I
title_full_unstemmed Efeito analgésico da melatonina em um modelo animal da síndrome de dor complexa regional tipo I
title_sort Efeito analgésico da melatonina em um modelo animal da síndrome de dor complexa regional tipo I
author Mack, Josiel Mileno
author_facet Mack, Josiel Mileno
author_role author
dc.contributor.none.fl_str_mv Santos, Adair Roberto Soares dos
http://lattes.cnpq.br/9263042062534666
Mello, Carlos Fernando de
Nascimento, Francisney Pinto do
Furian, Ana Flávia
dc.contributor.author.fl_str_mv Mack, Josiel Mileno
dc.subject.por.fl_str_mv Síndrome de dor complexa regional tipo I
Dor crônica pós-isquemia
Melatonina
Estresse oxidativo
Enzimas antioxidantes
Complex regional pain syndrome-type I
Chronic post-ischemic pain
Melatonin
Oxidative stress
Antioxidant enzymes
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
topic Síndrome de dor complexa regional tipo I
Dor crônica pós-isquemia
Melatonina
Estresse oxidativo
Enzimas antioxidantes
Complex regional pain syndrome-type I
Chronic post-ischemic pain
Melatonin
Oxidative stress
Antioxidant enzymes
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
description Complex regional pain syndrome-type I (CRPS-I) affects upper or lower limbs distal parts, leading symptoms like chronic pain, edema, trophic changes and motor function abnormalities. This syndrome commonly follows factures and sprains. The pathophysiology of CRPS-I is not completely understood and its suggested that microvessels changes related to the syndrome maintenance lead to a reduction in oxygen supply. In this study the objective was to evaluation the time course of the antinociceptive activity of melatonin, an endogenous indolamine released mainly by pineal gland, in the mechanical and cold hypersensitivity and in the edema presented in the chronic post-ischemic pain (CPIP) in mice; an animal model of human CRPS-I, and participation of MT1/MT2 receptors and oxidative stress in this model. The antinociceptive activity of melatonin in the nociception evoked by TRPs (transient receptors potential) and ASICs (acid-sensing ion channels). CPIP was induced in Swiss male mice by placing a tourniquet proximal to the ankle joint for 3 hours, followed by removal to allow tissue reperfusion. The mechanical (0.4 g von Frey filaments) and cold (cold plate 4 ºC) hypersensitivity was mensured on second and seventh days after reperfusion. Catalase (CAT), glutathione reductase (GR) and glutathione peroxidase (GPx) enzyme activity and malondialdehyde (MDA) levels were measured 2 h, 2 and 7 days after reperfusion, tissues were collected 30 min after melatonin treatment (100 mg/kg, i.p.). Melatonin activity (10 – 100 mg/kg, i.p., or 10 – 100 ng/paw, i.pl.) was also evaluated by measuring of nociception evoked by TRPV1 agonists (capsaicin, 30,5 ng/paw, i.pl.), TRPA1 (cinnamaldehyde, 1,32 μg/paw), TRPM8 (menthol, 1.2 μg/paw) and ASICs (acetic acid 2%, pH 1.98). The treatment with melatonin (10-100 mg/kg, i.p.) dose-dependently reduced the mechanical hypersensitivity 2 and 7 days after reperfusion and with 100 mg/kg the effect remained by for up 2 h after administration. Furthermore, the treatment with melatonin (100 mg/kg, i.p.) also reduced the cold hypersensitivity 2 and 7 days after reperfusion. However, the melatonin effect (100 mg/kg) was not affected by pretreatment with luzindole (10 mg/kg, i.p., non-selective MT1/MT2 antagonist). The melatonin (100 mg/kg, i.p.) also reduced the edema evoked by CPIP in the second day after reperfusion. GR enzyme activity was reduced 2 h after reperfusion and melatonin treatment didn´t change this parameter. GR and GPx, and, Cat and GPx enzymes activities were elevated on days 2 and 7, respectively, and melatonin reversed this increase. The systemic administration (i.p.) of melatonin inhibited the nociception evoked by capsaicin, cinnamaldehyde, menthol and acid saline, inhibitions of 63 + 16%, 41 + 13%, 62 + 10% e 47 + 12%, respectively. Moreover, the peripheral administration of melatonin only inhibited the nociception evoked by capsaicin (49 + 6%) and cinnamaldehyde (60 + 6%). In conclusion, this study extends the literature and shows that melatonin is able to reduce the mechanical and thermal hypersensitivity and the edema in the CPIP model, probably by a modulation of redox status of the cell through its antioxidant properties and inhibition of peripheral nociceptors.
publishDate 2013
dc.date.none.fl_str_mv 2013-02-18
2023-03-27T14:36:23Z
2023-03-27T14:36:23Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufsm.br/handle/1/28415
dc.identifier.dark.fl_str_mv ark:/26339/0013000005m8c
url http://repositorio.ufsm.br/handle/1/28415
identifier_str_mv ark:/26339/0013000005m8c
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Farmacologia
UFSM
Programa de Pós-Graduação em Farmacologia
Centro de Ciências da Saúde
publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Farmacologia
UFSM
Programa de Pós-Graduação em Farmacologia
Centro de Ciências da Saúde
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com
_version_ 1814439735583571968